Note: Cover -- Title Page -- Copyright -- Contents -- About the Series Editors -- Chapter 1 Platform Technology for Therapeutic Protein Production -- 1.1 Introduction -- 1.2 Overall Trend Analysis -- 1.2.1 Mammalian Cell Lines -- 1.2.2 Brief Introduction of Advances and Techniques -- 1.3 General Guidelines for Recombinant Cell Line Development -- 1.3.1 Host Selection -- 1.3.2 Expression Vector -- 1.3.3 Transfection/Selection -- 1.3.4 Clone Selection -- 1.3.4.1 Primary Parameters During Clone Selection -- 1.3.4.2 Clone Screening Technologies -- 1.4 Process Development -- 1.4.1 Media Development -- 1.4.2 Culture Environment -- 1.4.3 Culture Mode (Operation) -- 1.4.4 Scale‐up and Single‐Use Bioreactor -- 1.4.5 Quality Analysis -- 1.5 Downstream Process Development -- 1.5.1 Purification -- 1.5.2 Quality by Design (QbD) -- 1.6 Trends in Platform Technology Development -- 1.6.1 Rational Strategies for Cell Line and Process Development -- 1.6.2 Hybrid Culture Mode and Continuous System -- 1.6.3 Recombinant Human Cell Line Development for Therapeutic Protein Production -- 1.7 Conclusion -- Acknowledgment -- Conflict of Interest -- References -- Chapter 2 Cell Line Development for Therapeutic Protein Production -- 2.1 Introduction -- 2.2 Mammalian Host Cell Lines for Therapeutic Protein Production -- 2.2.1 CHO Cell Lines -- 2.2.2 Human Cell Lines -- 2.2.3 Other Mammalian Cell Lines -- 2.3 Development of Recombinant CHO Cell Lines -- 2.3.1 Expression Systems for CHO Cells -- 2.3.2 Cell Line Development Process Using CHO Cells Based on Random Integration -- 2.3.2.1 Vector Construction -- 2.3.2.2 Transfection and Selection -- 2.3.2.3 Gene Amplification -- 2.3.2.4 Clone Selection -- 2.3.3 Cell Line Development Process Using CHO Cells Based On Site‐Specific Integration -- 2.4 Development of Recombinant Human Cell Lines -- 2.4.1 Necessity for Human Cell Lines. , 2.4.2 Stable Cell Line Development Process Using Human Cell Lines -- 2.5 Important Consideration for Cell Line Development -- 2.5.1 Clonality -- 2.5.2 Stability -- 2.5.3 Quality of Therapeutic Proteins -- 2.6 Conclusion -- References -- Chapter 3 Transient Gene Expression‐Based Protein Production in Recombinant Mammalian Cells -- 3.1 Introduction -- 3.2 Gene Delivery: Transient Transfection Methods -- 3.2.1 Calcium Phosphate‐Based Transient Transfection -- 3.2.2 Electroporation -- 3.2.3 Polyethylenimine‐Based Transient Transfection -- 3.2.4 Liposome‐Based Transient Transfection -- 3.3 Expression Vectors -- 3.3.1 Expression Vector Composition and Preparation -- 3.3.2 Episomal Replication -- 3.3.3 Coexpression Strategies -- 3.4 Mammalian Cell Lines -- 3.4.1 HEK293 Cell‐Based TGE Platforms -- 3.4.2 CHO Cell‐Based TGE Platforms -- 3.4.3 TGE Platforms Using Other Cell Lines -- 3.5 Cell Culture Strategies -- 3.5.1 Culture Media for TGE -- 3.5.2 Optimization of Cell Culture Processes for TGE -- 3.5.3 qp‐Enhancing Factors in TGE‐Based Culture Processes -- 3.5.4 Culture Longevity‐Enhancing Factors in TGE‐Based Culture Processes -- 3.6 Large‐Scale TGE‐Based Protein Production -- 3.7 Concluding Remarks -- References -- Chapter 4 Enhancing Product and Bioprocess Attributes Using Genome‐Scale Models of CHO Metabolism -- 4.1 Introduction -- 4.1.1 Cell Line Optimization -- 4.1.2 CHO Genome -- 4.1.2.1 Development of Genomic Resources of CHO -- 4.1.2.2 Development of Transcriptomics and Proteomics Resources of CHO -- 4.2 Genome‐Scale Metabolic Model -- 4.2.1 What Is a Genome‐Scale Metabolic Model -- 4.2.2 Reconstruction of GEMs -- 4.2.2.1 Knowledge‐Based Construction -- 4.2.2.2 Draft Reconstruction -- 4.2.2.3 Curation of the Reconstruction -- 4.2.2.4 Conversion to a Computational Format -- 4.2.2.5 Model Validation and Evaluation -- 4.3 GEM Application. , 4.3.1 Common Usage and Prediction Capacities of Genome‐Scale Models -- 4.3.2 GEMs as a Platform for Omics Data Integration, Linking Genotype to Phenotype -- 4.3.3 Predicting Nutrient Consumption and Controlling Phenotype -- 4.3.4 Enhancing Protein Production and Bioprocesses -- 4.3.5 Case Studies -- 4.4 Conclusion -- Acknowledgments -- References -- Chapter 5 Genome Variation, the Epigenome and Cellular Phenotypes -- 5.1 Phenotypic Instability in the Context of Mammalian Production Cell Lines -- 5.2 Genomic Instability -- 5.3 Epigenetics -- 5.3.1 DNA Methylation -- 5.3.2 Histone Modifications -- 5.3.3 Downstream Effectors -- 5.3.4 Noncoding RNAs -- 5.4 Control of CHO Cell Phenotype by the Epigenome -- 5.5 Manipulating the Epigenome -- 5.5.1 Global Epigenetic Modification -- 5.5.1.1 Manipulating Global DNA Methylation -- 5.5.1.2 Manipulating Global Histone Acetylation -- 5.5.2 Targeted Epigenetic Modification -- 5.5.2.1 Targeted Histone Modification -- 5.5.2.2 Targeted DNA Methylation -- 5.6 Conclusion and Outlook -- References -- Chapter 6 Adaption of Generic Metabolic Models to Specific Cell Lines for Improved Modeling of Biopharmaceutical Production and Prediction of Processes -- 6.1 Introduction -- 6.1.1 Constraint‐Based Models -- 6.1.2 Limitations of Flux Balance Analysis -- 6.1.2.1 Thermodynamically Infeasible Cycles -- 6.1.2.2 Genetic Regulation -- 6.1.2.3 Limitation of Intracellular Space -- 6.1.2.4 Multiple States in the Solution -- 6.1.2.5 Biological Objective Function -- 6.1.2.6 Kinetics and Metabolite Concentrations -- 6.2 Main Source of Optimization Issues with Large Genome‐Scale Models: Thermodynamically Infeasible Cycles -- 6.2.1 Definition of Thermodynamically Infeasible Fluxes -- 6.2.2 Loops Involving External Exchange Reactions -- 6.2.2.1 Reversible Passive Transporters from Major Facilitator Superfamily (MFS). , 6.2.2.2 Reversible Passive Antiporters from Amino Acid‐Polyamine‐organoCation (APC) Superfamily -- 6.2.2.3 Na+‐linked Transporters -- 6.2.2.4 Transport via Proton Symport -- 6.2.3 Tools to Identify Thermodynamically Infeasible Cycles -- 6.2.3.1 Visualizing Fluxes on a Network Map -- 6.2.3.2 Algorithms Developed -- 6.2.4 Methods Available to Remove Thermodynamically Infeasible Cycles -- 6.2.4.1 Manual Curation -- 6.2.4.2 Software and Algorithms Developed for the Removal of Thermodynamically Infeasible Loops from Flux Distributions -- 6.3 Consideration of Additional Biological Cellular Constraints -- 6.3.1 Genetic Regulation -- 6.3.1.1 Advantages of Considering Gene Regulation in Genome‐Scale Modeling -- 6.3.1.2 Methods Developed to Take into Account a Feedback of FBA on the Regulatory Network -- 6.3.2 Context Specificity -- 6.3.2.1 What Are Context‐Specific Models (CSMs)? -- 6.3.2.2 Methods and Algorithms Developed to Reconstruct Context‐Specific Models (CSMs) -- 6.3.2.3 Performance of CSMs -- 6.3.2.4 Cautions About CSMs -- 6.3.3 Molecular Crowding -- 6.3.3.1 Consequences on the Predictions -- 6.3.3.2 Methods Developed to Account for a Total Enzymatic Capacity into the FBA Framework -- 6.4 Conclusion -- References -- Chapter 7 Toward Integrated Multi‐omics Analysis for Improving CHO Cell Bioprocessing -- 7.1 Introduction -- 7.2 High‐Throughput Omics Technologies -- 7.2.1 Sequencing‐Based Omics Technologies -- 7.2.1.1 Historical Developments of Nucleotide Sequencing Techniques -- 7.2.1.2 Genome Sequencing of CHO Cells -- 7.2.1.3 Transcriptomics of CHO Cells -- 7.2.1.4 Epigenomics of CHO Cells -- 7.2.2 Mass Spectrometry‐Based Omics Technologies -- 7.2.2.1 Mass Spectrometry Techniques -- 7.2.2.2 Proteomics of CHO Cells -- 7.2.2.3 Metabolomics/Lipidomics of CHO Cells -- 7.2.2.4 Glycomics of CHO Cells -- 7.3 Current CHO Multi‐omics Applications. , 7.3.1 Bioprocess Optimization -- 7.3.2 Cell Line Characterization -- 7.3.3 Engineering Target Identification -- 7.4 Future Prospects -- References -- Chapter 8 CRISPR Toolbox for Mammalian Cell Engineering -- 8.1 Introduction -- 8.2 Mechanism of CRISPR/Cas9 Genome Editing -- 8.3 Variants of CRISPR‐RNA‐guided Endonucleases -- 8.3.1 Diversity of CRISPR/Cas Systems -- 8.3.2 Engineered Cas9 Variants -- 8.4 Experimental Design for CRISPR‐mediated Genome Editing -- 8.4.1 Target Site Selection and Design of gRNAs -- 8.4.2 Delivery of CRISPR/Cas9 Components -- 8.5 Development of CRISPR/Cas9 Tools -- 8.5.1 CRISPR/Cas9‐mediated Gene Editing -- 8.5.1.1 Gene Knockout -- 8.5.1.2 Site‐Specific Gene Integration -- 8.5.2 CRISPR/Cas9‐mediated Genome Modification -- 8.5.2.1 Transcriptional Regulation -- 8.5.2.2 Epigenetic Modification -- 8.5.3 RNA Targeting -- 8.6 Genome‐Scale CRISPR Screening -- 8.7 Applications of CRISPR/Cas9 for CHO Cell Engineering -- 8.8 Conclusion -- Acknowledgment -- References -- Chapter 9 CHO Cell Engineering for Improved Process Performance and Product Quality -- 9.1 CHO Cell Engineering -- 9.2 Methods in Cell Line Engineering -- 9.2.1 Overexpression of Engineering Genes -- 9.2.2 Gene Knockout -- 9.2.3 Noncoding RNA‐mediated Gene Silencing -- 9.3 Applications of Cell Line Engineering Approaches in CHO Cells -- 9.3.1 Enhancing Recombinant Protein Production -- 9.3.2 Repression of Cell Death and Acceleration of Growth -- 9.3.3 Modulation of Posttranslational Modifications to Improve Protein Quality -- 9.4 Conclusions -- References -- Chapter 10 Metabolite Profiling of Mammalian Cells -- 10.1 Value of Metabolic Data for the Enhancement of Recombinant Protein Production -- 10.2 Technologies Used in the Generation of Metabolic Data Sets -- 10.2.1 Targeted and Untargeted Metabolic Analysis. , 10.2.2 Analytical Technologies Used in the Generation of Metabolite Profiles.